172 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
8230117	4	The crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)- 4-methoxyphenyl)-pyrrolidin-2-one.	Smithkline Beecham Pharmaceuticals
1479586	8	New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.	Kyowa Hakko Kogyo
1656043	4	New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.	Universidad De Navarra
2153209	6	Synthesis and cardiotonic activity of novel biimidazoles.	Merrell Dow Research Institute
2738882	9	Synthesis of a tritium-labeled indolidan analogue and its use as a radioligand for phosphodiesterase-inhibitor cardiotonic binding sites.	Eli Lilly
2846840	20	Inhibitors of cyclic AMP phosphodiesterase. 4. Synthesis and evaluation of potential prodrugs of lixazinone (N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2- oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide, RS-82856).	Syntex Research
3039132	26	Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents.	TBA
3965705	10	2-(beta-Arylethylamino)- and 4-(beta-arylethylamino)quinazolines as phosphodiesterase inhibitors.	TBA
14980691	15	Orally active PDE4 inhibitors with therapeutic potential.	Minase Research Institute
14684291	14	New orally active PDE4 inhibitors with therapeutic potential.	Minase Research Institute
14684329	27	Highly potent PDE4 inhibitors with therapeutic potential.	Minase Research Institute
12668000	29	3D-QSAR studies on thieno[3,2-d]pyrimidines as phosphodiesterase IV inhibitors.	National Institute of Pharmaceutical Education and Research (NIPER)
12852946	69	Comparative molecular field analysis (CoMFA) of phthalazine derivatives as phosphodiesterase IV inhibitors.	National Institute of Pharmaceutical Education and Research
12824031	26	Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.	Tanabe Seiyaku
11814830	26	7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.	Celltech R&D
12039576	17	Synthesis and profile of SCH351591, a novel PDE4 inhibitor.	Schering-Plough
12039575	18	8-Methoxyquinolines as PDE4 inhibitors.	Schering-Plough
12039574	16	8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.	Celltech R&D
11738561	34	Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.	Zambon Group
11140727	31	Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.	Zambon Group
11128646	69	Synthesis and biological evaluation of 2,5-dihydropyrazol.	RhôNe-Poulenc Rorer
11012037	25	The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.	Zambon Group
10999488	34	7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.	Celltech-Chiroscience
10636238	71	Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.	Institut De Recherche Jouveinal-Parke Davis
9871607	32	Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds.	RhôNe-Poulenc Rorer
9871693	46	Quaternary substituted PDE IV inhibitors II: the synthesis and in vitro evaluation of a novel series of gamma-lactams.	Rh£Ne-Poulenc Rorer Central Research
9873675	44	Orally active indole N-oxide PDE4 inhibitors.	Rh£Ne-Poulenc Rorer Central Research
9873649	25	PDE4 inhibitors: new xanthine analogues.	Chiroscience
9871649	26	Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.	Rh£Ne-Poulenc Rorer Central Research
9873600	14	Thalidomide analogs and PDE4 inhibition.	Celgene
9873613	15	2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.	Rh£Ne-Poulenc Rorer
9873593	15	Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.	Chiroscience
9873449	49	The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.	Rh£Ne-Poulenc Rorer Central Research
27597413	58	Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.	Southern Medical University
26789933	100	Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.	Intra-Cellular Therapies
26681511	33	Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors.	Sanofi Research Center
26562545	13	Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.	Institute of Radiopharmaceutical Cancer Research
26526739	35	Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.	Southern Medical University
26430878	102	Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate.	Washington University
26288683	43	Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.	Bristol-Myers Squibb R & D
26288344	15	Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).	Novartis Institutes For Biomedical Research
25592707	31	Synthesis and in vitro characterization of cinnoline and benzimidazole analogues as phosphodiesterase 10A inhibitors.	Washington University
26005524	147	Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.	Merck Research Laboratories
25801159	36	Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.	Csir-Indian Institute of Integrative Medicine
25736998	37	Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.	Merck Serono
24785301	83	Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.	Astrazeneca
9873708	16	N-arylrolipram derivatives as potent and selective PDE4 inhibitors.	Novartis Horsham Research Center
23421315	18	Novel inhibitors of protein arginine deiminase with potential activity in multiple sclerosis animal model.	University Health Network
23260348	91	Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.	Janssen-Cilag
22963052	38	Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.	Vu University Amsterdam
22891752	18	Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.	Universidade Federal Do Rio De Janeiro
22889281	36	Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.	Novartis Institutes For Biomedical Research
21456625	41	Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).	University of Glasgow
18686943	28	Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.	Matrix Laboratories
17228876	36	SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.	Pfizer
16168647	80	Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.	Merck Frosst Centre For Therapeutic Research
15887951	29	The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.	Monash University (Parkville Campus)
11405657	123	Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.	Tanabe Seiyaku
10691693	64	Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.	Novartis Pharma
10090791	77	Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.	Tanabe Seiyaku
8388468	37	Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.	Smithkline Beecham Pharmaceuticals
12824030	67	1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.	Tanabe Seiyaku
12270195	15	Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.	Merck Frosst Centre For Therapeutic Research
11755362	24	Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.	Novartis Pharma
12031319	46	Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.	Merck Frosst Centre For Therapeutic Research
21988093	316	Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.	Pfizer
21955943	47	Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.	Pfizer
21983442	142	Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.	Biocrea
21871695	46	Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.	RhôNe-Poulenc Rorer
20933411	69	Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.	Merck Frosst Centre For Therapeutic Research
20825218	69	Synthesis and biological activity of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.	RhôNe-Poulenc Rorer
20709547	69	The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.	Merck Frosst Centre For Therapeutic Research
20450197	80	Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.	Biotie Therapies
20196613	32	Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).	Pfizer
19631533	126	Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.	Pfizer
	5	The Gif system as a tool in medicinal chemistry: The oxidation of Sch 57726 under GoAggIII conditions	TBA
19339180	69	The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.	Pfizer
18945617	50	Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.	Pfizer
18835163	41	Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.	Merck Frosst Center For Therapeutic Research
16516471	114	Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.	Merck Frosst Center For Therapeutic Research
16275071	26	A new chemical tool for exploring the physiological function of the PDE2 isozyme.	Pfizer
16263279	37	A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.	Pfizer
15149695	24	New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.	Pfizer
14521415	44	The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.	Glaxosmithkline
12773045	27	Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.	Merck Frosst Centre For Therapeutic Research
12749899	17	Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.	Merck Frosst Centre For Therapeutic Research
12639571	24	Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors.	Merck Frosst Centre For Therapeutic Research
12031318	45	CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.	Celltech R&D
11958981	25	Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors.	Bayer
32209292	6	Ultrasound assisted rapid synthesis of mefenamic acid based indole derivatives under ligand free Cu-catalysis: Their pharmacological evaluation.	Andhra University
32171616	32	Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.	Changzhou University
11052785	14	Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).	Merck Frosst Centre For Therapeutic Research
10937713	186	Solid-phase synthesis of an arylsulfone hydroxamate library.	Rhone-Poulenc Rorer
26908025	164	PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.	Vrije Universiteit Amsterdam
32115956	46	Discovery and Optimization of ?-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.	Guangzhou University of Chinese Medicine
31099559	36	Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.	Shanghai Institute of Materia Medica
31021628	50	Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.	Chinese Academy of Sciences
10197972	133	1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.	Tanabe Seiyaku
10091677	15	Substituted furans as inhibitors of the PDE4 enzyme.	Merck Frosst Centre For Therapeutic Research
30554955	34	Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.	Changzhou University
9873643	75	Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.	Novartis Pharma
9873594	44	Aryl sulfonamides as selective PDE4 inhibitors.	Chiroscience
30888810	48	Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.	Sun Yat-Sen University
31235264	13	Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.	Mitsubishi Tanabe Pharma
30986068	112	Structure Overhaul Affords a Potent Purine PI3K? Inhibitor with Improved Tolerability.	TBA
32071685	40	Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGF?R1 Inhibitor as an Immuno-oncology Agent.	Bristol-Myers Squibb Research & Development
9464356	24	Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.	Pfizer
8496906	127	Bronchodilator activity of xanthine derivatives substituted with functional groups at the 1- or 7-position.	Hokuriku University
25062128	16	Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A).	Amgen
24794103	1	Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.	Dainippon Sumitomo Pharma
23585921	52	Synthesis and	Washington University School of Medicine
24400806	101	Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.	Chiesi Farmaceutici
23582272	25	Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.	Pfizer
21955454	53	1,1-Diarylalkenes as anticancer agents: dual inhibitors of tubulin polymerization and phosphodiesterase 4.	Celgene
20413313	14	Functionalized pyrazoles and pyrazolo[3,4-d]pyridazinones: Synthesis and evaluation of their phosphodiesterase 4 inhibitory activity.	Universit£
15916433	10	Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: application to the structure-based optimization of a phosphodiesterase 4 inhibitor.	Umr Cnrs 7081
12723963	41	Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.	Vrije Universiteit
12036361	28	Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.	Vrije Universiteit
12036360	58	Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.	Vrije Universiteit
12014973	3	Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers.	Wyeth Research
11472206	72	Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.	Vrije Universiteit
11472205	37	Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.	Vrije Universiteit
10737755	8	Novel and selective calcitonin-inducing agents.	Wyeth-Ayerst Research
11123995	113	Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.	Pfizer
9526558	38	1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.	Smithkline Beecham Pharmaceuticals
9822544	15	Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth.	University of Kaiserslautern
9784096	38	Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.	Sw 8 Rh£Ne-Poulenc Rorer Central Research
9767640	122	Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.	RhôNe-Poulenc Rorer
9632360	26	7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.	Pfizer
9379444	54	Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.	Hokuriku University
9154964	25	Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.	Dipartimento Di Scienze Farmaceutiche, Firenze, Italy.
8568798	29	Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.	Pfizer
30052440	5	Lead-like Drugs: A Perspective.	Pfizer
30245400	167	Discovery of furyl/thienyl ?-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect.	Shandong University
29353721	63	Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.	Seoul National University
2544722	94	Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.	Centre De Neurochimie Du Cnrs
29152042	32	Selective Inhibitors of Phosphodiesterase 4B (PDE-4B) May Provide a Better Treatment for CNS, Metabolic, Autoimmune, and Inflammatory Diseases.	Therachem Research Medilab (India)
28698053	2	Stable C-N axial chirality in 1-aryluracil scaffold and differences in in vitro metabolic clearance between atropisomers of PDE4 inhibitor.	Osaka University
28613871	18	Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38? MAPK/PDE-4 Inhibitor with Activity against TNF?-Related Diseases.	C-A-I-R Biosciences
1331453	106	Effects of alkyl substitutions of xanthine skeleton on bronchodilation.	Hokuriku University
10963748	3	The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor.	University of Frankfurt
9349523	22	Cloning and expression of a human serotonin 5-HT4 receptor cDNA.	Janssen Research Foundation
9305929	19	Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover.	Synaptic Pharmaceutical
9303569	35	Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist.	RhôNe-Poulenc Rorer
17643112	12	Splicing factor SF3b as a target of the antitumor natural product pladienolide.	Eisai
18790640	22	Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.	Abbott Laboratories
17629487	20	Alpha-substituted N-(4-tert-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as potent and stereospecific TRPV1 antagonists.	Seoul National University
16460932	27	Discovery of novel heterocyclic factor VIIa inhibitors.	Celera